

Amendments to the Claims

Claims 1-35 (cancelled).

36. (previously amended) A tumor vaccine for administration to a patient, wherein said tumor vaccine comprises tumor cells which present a first set of peptides in an HLA context, wherein said first set of peptides are derived from tumor antigens, and wherein at least some of said tumor cells have at least one MHC-I haplotype of said patient on the cell surface, and wherein said tumor cells further comprise a second set of peptides which bind the peptide binding fork of said MHC-I haplotype and wherein said second set of peptides are selected from the group consisting of:

(a) peptides which are different from peptides which are derived from proteins expressed by the cells of said patient; and

(b) peptides which are derived from tumor antigens which are expressed by said patient's cells and are present at a higher concentration on said tumor cells of said vaccine than on said patient's cells;

and wherein said tumor cells have been incubated in the presence of an organic polycation with one or more said peptides (a) or (b) or both (a) and (b) in such a way that said tumor cells are recognized as foreign by the immune system of said patient and trigger a cellular immune response in said patient;

and wherein said organic polycation is selected from the group consisting of polylysine, polyarginine, polyornithine, polyethyleneimines, histones, protamines, spermine and spermidines;

Enter
10/22/2003